---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-029397"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2021-11-19T23:59:59+00:00"
generated_at: "2026-06-28T06:40:40.957558+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics appoints Samuel J. Reich as Executive Chairman; $350K salary, 350K share option.

## Summary
- Reich named Executive Chairman effective Oct 25, 2021; reports to Board of Directors.
- Annual base salary of $350,000; eligible for annual cash bonus of at least 50% of base salary.
- Granted nonqualified stock option for 350,000 shares vesting over three years (1/3 year 1, remainder monthly).
- Severance: 12 months salary + COBRA if terminated without cause/good reason; 24 months if in change of control period.
- Agreement includes standard restrictive covenants (non-disclosure, non-compete, non-solicitation).

## SEC filing metadata
- accession: 0001493152-21-029397
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2021-11-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000149315221029397/0001493152-21-029397-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000149315221029397/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-029397
- JSON: https://secwatch.observer/filing/0001493152-21-029397.json
- Plain text: https://secwatch.observer/filing/0001493152-21-029397.txt

## Key facts
- Executive change
  Samuel J. Reich was appointed as Executive Chairman of the Board of Directors at SAB Biotherapeutics, Inc..
  - Action: appointed
  - Role: Executive Chairman of the Board of Directors
  source text: On November 17, 2021, and effective as of October 25, 2021, SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”) entered into an Executive Employment Agreement with Mr. Samuel J. Reich (the “Agreement”) to serve as the Company’s Executive Chairman of the Board of Directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833214/000149315221029397/0001493152-21-029397-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.